This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.

开始日期2025-12-01

申办/合作机构

Akcea Therapeutics, Inc.

NCT04306510

/ Terminated临床4期

A Phase 4 Safety Study Assessing the Adverse Events Occurring Within One Day of TEGSEDI Administration in Patients With Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis (hATTR-PN)

The objective of the study was to characterize adverse events (AEs) occurring within one day of TEGSEDI administration to adult participants with hATTR-PN overall and in individual participants with respect to time course of AE onset, vital sign changes, preventive measures, treatment required, risk factors, and subsequent adverse outcomes.

开始日期2021-01-21

申办/合作机构

Akcea Therapeutics, Inc.

NCT03702829

/ Terminated临床2期IIT

24 Month Open Label Study of the Tolerability and Efficacy of an Antisense Oligonucleotide (Inotersen) in Patients With Transthyretin (TTR) Amyloid Cardiomyopathy

Transthyretin is a protein produced in the liver that transports thyroid hormone and vitamin A. A single substitution of an amino acid in the structure of TTR can result in a relatively unstable protein, the breakdown products of which (predominantly monomers) aggregate abnormally and produce proteinaceous deposits in nerves and the heart. These deposits are known as amyloid and produce progressive nerve and heart damage. Amyloidosis due to a mutant TTR is usually an autosomal dominant and hence is a familial condition. Wild-type TTR is also capable of producing amyloid deposits which predominantly involves the heart (rather than the nervous system) resulting in a progressive decrease in cardiac function with increasing signs of heart failure. This study aims to determine whether subcutaneous injection of an antisense oligonucleotide drug, known as inotersen, that has been specifically designed to reduce production of the protein transthyretin by the liver, can slow or stop the progression of TTR amyloid cardiomyopathy as compared to historical controls, using advanced echocardiography and cardiac MRI. The study also aims to determine the tolerability and safety of this drug when administered over a 24-month period to patients with TTR amyloid cardiomyopathy.

开始日期2019-02-28

申办/合作机构

The Brigham & Women's Hospital, Inc.

100 项与伊诺特森相关的临床结果

登录后查看更多信息

100 项与伊诺特森相关的转化医学

登录后查看更多信息

100 项与伊诺特森相关的专利（医药）

登录后查看更多信息

项与伊诺特森相关的文献（医药）

2026-02-01·European Journal of Internal Medicine

Precision medicine with pioneering RNAi therapeutics in ATTR amyloidosis: from bench to bedside

Review

作者: Porcari, Aldostefano ; Verona, Guglielmo ; Vergaro, Giuseppe ; Malinverni, Silvia

Transthyretin (ATTR) amyloidosis is a multisystem disease caused by misfolding and aggregation of the plasma protein transthyretin (TTR) into insoluble amyloid fibrils in various organs. In clinical practice, ATTRwt amyloidosis manifests as a predominant cardiomyopathy (ATTR-CM), while ATTRv amyloidosis is typically associated with polyneuropathy (ATTR-PN) as well as cardiomyopathy. Over the past decade, major advances in the understanding of ATTR pathophysiology have enabled the development of disease-modifying therapies, marking a paradigm shift toward precision medicine in this condition. Among these, RNA-targeted therapies have emerged as a cornerstone of treatment by directly suppressing hepatic production of TTR. This review provides an overview of the biological rationale, molecular mechanisms, and clinical translation of RNA-based therapeutics in ATTR amyloidosis, with a particular focus on RNA interference (RNAi) and antisense oligonucleotide (ASO) strategies. Key mechanistic differences between small interfering RNAs and ASOs are discussed, including intracellular pathways, pharmacokinetic properties, and delivery platforms such as lipid nanoparticles and GalNAc conjugation for hepatocyte-specific targeting. Major clinical trials evaluating first- and second-generation RNA-targeted agents-including patisiran, vutrisiran, inotersen, and eplontersen-are summarized, highlighting efficacy, safety profiles, dosing regimens, and relevance across different ATTR phenotypes. As RNA-based therapies continue to evolve, integration of molecular insights with clinical phenotyping and real-world evidence will be essential to fully realize the potential of precision medicine for patients with ATTR amyloidosis.

2026-02-01·HEART

Current and emerging treatment options for transthyretin amyloid cardiomyopathy

Review

作者: Aimo, Alberto ; Ferrari Chen, Yu Fu ; Panichella, Giorgia ; Ioannou, Adam ; Fontana, Marianna ; Castiglione, Vincenzo ; Vergaro, Giuseppe ; Emdin, Michele

Transthyretin amyloidosis (ATTR) is a condition caused by TTR protein misfolding and amyloid deposition, particularly in the heart and nervous system, leading to organ dysfunction. Advances in therapeutic strategies have revolutionised the management of ATTR amyloidosis. Treatments available in clinical practice include TTR stabilisers (tafamidis and acoramidis), which prevent the dissociation of TTR tetramer into monomers and oligomers that subsequently form amyloid fibrils, and gene-silencing therapies (patisiran, inotersen and vutrisiran), which suppress the hepatic synthesis of TTR, which is the amyloid precursor protein. Novel treatment strategies that are at various stages of development include Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 gene-editing technology (nexiguran ziclumeran), which, if successful, offers the prospect of a single-dose treatment, and monoclonal (cormitug and ALXN220) and pan-amyloid antibodies (AT-02) that seek to target and remove amyloid fibrils that have deposited in the myocardium. Amyloid removal remains a significant unmet clinical need, and hence, the ability to promote amyloid degradation and clearance through the use of antiamyloid therapies would represent a groundbreaking advancement in the treatment of ATTR amyloidosis. The success of ATTR-specific disease-modifying therapies has already altered the treatment landscape and changed the perception of ATTR amyloidosis from a progressive and fatal disease to one that is treatable through the availability of highly effective disease-modifying therapies. However, important questions remain, including the long-term safety of these drugs, whether combining therapies with different mechanisms of action has an additive prognostic benefit and how best to monitor the treatment response.

2026-01-01·CJC open

Detecting Polyneuropathy in Patients with Hereditary Transthyretin Amyloid Cardiomyopathy

Article

作者: Basile, Vincenzo Santo ; Bril, Vera ; Loza, Rodrigo Carrasco ; Desai, Jamsheed ; Nugaeva, Natalia ; Delgado, Diego ; Katzberg, Hans ; Arivalagan, Priya

Background:

Patients with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM), can show neurologic signs that lead to the eventual onset of polyneuropathy (PN). Detection of PN among patients with hATTR-CM can identify candidates for disease-modifying therapies that could significantly reduce the incidence of mortality and morbidity for these complex patients. The purpose of this study is to determine the prevalence of PN among patients with hATTR-CM.

Methods:

Sixty patients with hATTR-CM were enrolled in this prospective study, from the Amyloidosis Clinic at the University Health Network in Toronto, Ontario, Canada. All patients (average age: 69.12 ± 11.82 years; 51.7% male; 48.3% female) were referred to neurology programs specialized in hATTR PN. Comprehensive neurologic assessments were conducted, including a physical examination and nerve conduction studies (NCSs). NCSs were performed on the upper and lower extremities.

Results:

Thirty patients (50.0%) displayed clinical and NCS abnormalities. Six patients (10.0%) did not display any neurologic abnormalities on the physical examination, but did have abnormalities on the NCSs, suggesting the presence of transthyretin-PN. The abnormalities on the NCSs were more indicative of sensory PN than of motor polyneuropathy. Twenty-four patients (40.0%) did not display any clinical or NCS abnormalities. Based on the systematic neurologic assessment, 36 patients in our study were identified as having a mixed hATTR phenotype, and they are to receive specific disease-modifying therapies, either patisiran or inotersen.

Conclusion:

Patients with hATTR-CM should be systematically referred to a specialized neurologist for routine assessment, especially patients who report neurologic symptoms (ie, numbness and burning sensation in extremities).

171

项与伊诺特森相关的新闻（医药）

2026-02-23

·今日头条

托夫生研发

你作为临床医学硕士，要理解并推进 ATXN2-ASO 这类药物研发，核心是先吃透托夫生（Tofersen）的成功范式，再把这套逻辑迁移到 SCA2/ATXN2 上。下面我从托夫生如何成功、 ASO 药物研发全流程、你作为临床硕士的切入路径三部分，用临床 + 研发双视角讲透。一、托夫生（Tofersen）：SOD1-ASO 为何能成（FDA 2023 获批） 1. 核心成功逻辑（可直接套用于 ATXN2）靶点明确、机制清晰：SOD1 突变 → 毒性蛋白聚集 → 运动神经元死亡；ASO 降解突变 mRNA → 减少毒性蛋白 → 延缓 / 阻止疾病。技术成熟：ASO 化学修饰（硫代磷酸酯骨架、2’-O - 甲氧基乙基等）解决稳定性、免疫原性、递送问题。临床路径精准：鞘内注射（直接入 CSF，靶向中枢）。用 NF-L（神经丝轻链）作为替代终点，加速获批。聚焦 SOD1 突变型 ALS （小人群、精准），走罕见病加速通道。动物实验过硬：模型小鼠中降低 SOD1 蛋白、延长生存期、改善运动功能。 2. 托夫生关键技术要点（ASO 共性）序列设计：18–20 nt，互补于 SOD1 mRNA 编码区 / UTR，触发 RNase H 降解。化学修饰：全链硫代磷酸酯（PS）+ 部分 2’-MOE，提升血浆 / 组织稳定性、降低脱靶。递送方式：鞘内注射（IT），直接作用于中枢神经系统（CNS），避开血脑屏障。临床终点：以 CSF SOD1 下降 + NF-L 下降为生物标志物，功能终点（ALSFRS-R）作为次要验证。二、ASO 药物（如 ATXN2-ASO）完整研发流程（从 0 到上市）阶段 1：靶点验证与机制研究（1–2 年） 1. 靶点确认（你作为临床硕士最擅长）明确 ATXN2 CAG 重复扩增 → 多聚谷氨酰胺毒性蛋白 → 小脑 / 脑干神经元死亡 → SCA2 。验证：敲低 / 敲除 ATXN2 可改善模型表型；ASO 降低 ATXN2 mRNA / 蛋白 → 神经保护。关键：区分野生型与突变型 ATXN2 （优先降解突变 mRNA，减少对正常功能影响）。 2. 疾病模型构建细胞模型：ATXN2 突变 iPSC 分化神经元、SH-SY5Y 过表达突变 ATXN2。动物模型：SCA2 转基因小鼠（CAG 重复 ≥ 35），评估共济失调、生存期、病理。阶段 2：ASO 分子设计与筛选（1–2 年） 1. 序列设计（核心）靶标区域： ATXN2 mRNA 的 CAG 重复区、编码区、3’UTR （优先选突变特异性位点）。长度：16–22 nt（兼顾特异性与 RNase H 活性）。设计原则：避免自身二级结构、避免与人类其他基因高度同源（BLAST 验证）。优先靶向突变等位基因特异性序列（如 CAG 重复侧翼 SNP）。 2. 化学修饰（决定成药性）骨架修饰：硫代磷酸酯（PS）全链 / 部分替换，提升核酸酶抗性。糖修饰： 2’-O - 甲基（2’-OMe）、2’-MOE、锁核酸（LNA），提升亲和力、降低免疫原性。末端修饰：5’/3’ 端稳定化修饰，减少降解。 3. 体外筛选（细胞水平）检测：qPCR 测 ATXN2 mRNA 下降、Western 测蛋白、免疫荧光看毒性聚集。指标：敲低效率（≥70%）、特异性（不影响同源基因）、细胞毒性（CC₅₀ 高）。选出 5–10 个候选 ASO 进入体内。阶段 3：临床前体内研究（1–3 年） 1. 动物药效学（核心）模型：SCA2 转基因小鼠（CAG 重复 40–80）。给药：鞘内注射（IT）或侧脑室注射（ICV），模拟临床 CNS 递送。终点：分子：CSF / 脑组织 ATXN2 mRNA / 蛋白下降、多聚谷氨酰胺聚集减少。功能：旋转棒、足迹、平衡能力改善。病理：小脑萎缩减轻、神经元存活增加。生存：生存期延长。 2. 药代动力学（PK）检测：CSF / 血浆 / 脑组织 ASO 浓度、半衰期、组织分布。目标： CNS 暴露高、外周暴露低、半衰期长（减少给药频次）。 3. 安全性评价（GLP）急性 / 亚急性 / 慢性毒性：小鼠、大鼠、非人灵长类（NHP）。重点： CNS 毒性（脑膜炎、颅内压）、肝 / 肾毒性、免疫原性、脱靶效应。托夫生经验：7% 出现无菌性脑膜炎，可控、可逆。阶段 4：临床试验（3–7 年，最耗时） 1. I 期（安全性、PK、PD）人群：健康志愿者 + SCA2 患者（小样本，20–50 例）。给药：鞘内注射，梯度剂量（如 10 mg、30 mg、60 mg、100 mg）。终点：安全性、CSF ASO 浓度、 ATXN2 mRNA / 蛋白下降、NF-L 变化（生物标志物）。 2. II 期（有效性探索、剂量优化）人群：SCA2 患者（100–300 例，按 CAG 重复数 / 发病年龄分层）。设计：随机、双盲、安慰剂对照。终点：主要： SCA 功能评分（如 SCA 综合评分）下降速率减缓。次要：NF-L、MRI 小脑体积、生活质量。确定最优剂量与给药间隔（如每 3 个月一次）。 3. III 期（确证有效性，注册关键）人群：SCA2 患者（300–800 例，多中心）。设计：随机、双盲、安慰剂对照，长期随访（1–2 年）。终点：主要：功能终点达到统计学差异（如 SCA 评分恶化延迟）。次要：生物标志物、生存期、安全性。若功能终点未达，可借鉴托夫生，以 NF-L 等生物标志物申请加速批准。阶段 5：注册上市与商业化（1–2 年）提交 NDA/BLA，包含临床前 + 临床全部数据、生产工艺、质量控制。走罕见病、加速批准、优先审评通道（SCA2 属罕见病，符合条件）。上市后：IV 期临床（真实世界数据）、长期安全性监测。三、临床医学硕士：如何切入并做出 ATXN2-ASO 药物 1. 你的核心优势（临床视角不可替代）疾病机制理解：SCA2 临床表型、遗传规律、CAG 重复与发病年龄关系、中间型风险。临床终点设计：制定合理、敏感的功能评分（如 SCA 综合评分、共济失调量表）。患者招募与管理：建立 SCA2 患者队列、生物样本库（血液、CSF、iPSC）。转化医学桥梁：连接基础研究与临床，确保 ASO 研发贴合临床需求。 2. 分阶段能力建设与路径（1）夯实基础（0–1 年）系统学习： ASO 技术原理、化学修饰、递送、RNase H 机制。文献精读：托夫生、诺西那生（Nusinersen）、Inotersen 等 ASO 研发全流程。掌握工具：分子生物学（qPCR、Western、免疫荧光）、细胞培养、动物实验基础。（2）聚焦 ATXN2-ASO（1–3 年）建立合作：与分子生物学实验室、ASO CRO/CDMO、药企研发部合作。核心工作：构建 / 优化 SCA2 细胞 / 动物模型。设计并筛选 ATXN2 特异性 ASO （优先靶向突变等位基因）。开展临床前体内实验（药效、PK、安全性）。产出：发表论文、申请专利、形成候选 ASO 分子。（3）推进临床转化（3–7 年）申请课题：国家自然科学基金（转化医学）、罕见病专项、药企横向合作。搭建临床平台：建立 SCA2 患者登记与生物样本库。设计 I/II 期临床试验方案（聚焦安全性、生物标志物、早期疗效）。对接药企：将候选 ASO 授权给药企，或共同推进临床试验。 3. 关键资源与合作（缺一不可） ASO 合成与修饰：与专业 CRO（如 Ionis、Biogen 合作方、国内 CRO）合作。动物模型：自建或与模式动物中心合作 SCA2 转基因小鼠。临床资源：依托医院神经内科，建立 SCA2 专病门诊与患者队列。资金：纵向课题 + 药企合作 + 风险投资（罕见病基因药受资本青睐）。 4. 避坑要点（托夫生与 ASO 研发教训）靶点特异性：ATXN2 与其他多聚谷氨酰胺疾病（如 SCA1、3、6）同源性高，必须设计突变特异性 ASO ，避免脱靶。 CNS 递送：血脑屏障是最大障碍，鞘内注射是目前 CNS-ASO 最优递送方式。中间型风险：ATXN2 32–34 次重复是 “隐形炸弹”， ASO 需覆盖此类人群，早期干预。生物标志物：提前建立 CSF ATXN2 蛋白、NF-L、小脑 MRI 体积等标志物，为临床试验加速获批铺路。四、总结：ATXN2-ASO 成功 = 托夫生范式 + SCA2 特异性优化靶点：ATXN2 突变 mRNA → 降解 → 减少毒性多聚谷氨酰胺蛋白。技术：ASO 化学修饰 + 鞘内递送 + RNase H 机制。临床：以 NF-L、ATXN2 蛋白为生物标志物，聚焦 SCA2 患者，走罕见病加速通道。你的角色：以临床视角主导疾病机制、患者队列、临床终点、转化落地，与基础 / 药企团队协同。

2026-02-23

·产业智能官

【医药智能】生物医药RNA技术全景深度解析：siRNA、miRNA、ASO、mRNA、srRNA、AOC、RNA激活

生物医药RNA技术全景深度解析：siRNA、miRNA、ASO、mRNA、srRNA、AOC、RNA激活本文将从底层分子机制、核心技术突破、临床转化逻辑、优势与瓶颈、产业现状五大维度，对7大核心RNA技术进行系统性深度拆解，同时厘清技术间的本质区别与产业协同关系，覆盖从基础研究到商业化全链条的核心信息。一、技术总览：先建立核心分类框架 7大技术可按功能与定位分为四大类，彻底理清逻辑边界：技术分类包含技术核心功能定位基因沉默类 siRNA、miRNA、ASO（降解型）特异性抑制/下调致病基因表达，阻断坏蛋白生成蛋白表达类 mRNA、srRNA 给细胞提供蛋白合成模板，让细胞自主生产治疗性蛋白递送赋能类 AOC 解决RNA药物肝外递送痛点，实现全组织精准靶向基因激活类 RNA激活（saRNA/激活型ASO）上调内源有益基因表达，补充功能不足的好蛋白二、分技术深度拆解 1. siRNA（小干扰RNA，Small Interfering RNA）核心定义与分子本质 siRNA是长度为21-23nt的双链RNA分子，是RNA干扰（RNAi）通路的核心效应分子，为外源性设计合成的核酸药物，是目前RNA药物领域商业化最成熟的技术之一。底层作用机制 1.递送进入细胞质后，siRNA与Argonaute（Ago2）蛋白结合，组装成RNA诱导沉默复合体（RISC）； 2.RISC中的siRNA正义链被降解，保留反义链（引导链）； 3.引导链通过碱基完全互补配对识别靶标mRNA； 4.Ago2蛋白精准切割配对的mRNA，使其失去翻译能力，最终实现靶基因的特异性沉默。核心特点：作用位点为细胞质，仅针对成熟mRNA，完全配对决定了其单靶点、高特异性的属性。关键技术突破 •化学修饰：通过磷酸二酯键硫代（PS）修饰、2'-甲氧基（2'-OMe）、2'-氟（2'-F）修饰，解决了siRNA易被核酸酶降解、免疫原性高的问题； •GalNAc递送系统：三触角N-乙酰半乳糖胺（GalNAc）修饰，可特异性结合肝细胞表面高表达的去唾液酸糖蛋白受体（ASGPR），实现肝细胞的高效靶向摄取，同时受体可循环利用，大幅延长药效，实现半年一针的长效给药。核心优势与瓶颈核心优势现存瓶颈沉默效率极高（可达90%以上），靶点特异性强天然状态下无法穿透细胞膜，高度依赖递送系统长效性突出，给药频率远低于小分子与抗体绝大多数已商业化产品仅能靶向肝脏，肝外递送难度大靶点覆盖广，可靶向传统小分子/抗体“不可成药”靶点仅能实现基因沉默，无法解决基因表达不足的疾病临床应用与商业化现状 •已获批药物：全球已有超10款siRNA药物获批，核心代表为诺华的Inclisiran（高血脂，半年一针）、Alnylam的Patisiran（转甲状腺素蛋白淀粉样变性，ATTR）、Givosiran（急性肝卟啉症）； •核心适应症：罕见病、高血脂、高血压、慢性肝病、代谢性疾病，同时在肿瘤、神经疾病领域有大量临床管线布局。 2. miRNA（微小RNA，MicroRNA）核心定义与分子本质 miRNA是内源性、长度20-24nt的单链非编码RNA，是细胞自身基因表达调控的核心元件，药物开发基于对内源miRNA通路的干预，分为miRNA抑制剂与miRNA模拟物两大方向。底层作用机制 1.内源miRNA经pri-miRNA→pre-miRNA→成熟miRNA的生物发生过程，最终与RISC复合体结合； 2.成熟miRNA通过碱基不完全互补配对，识别靶mRNA的3'非翻译区（3'UTR）； 3.核心效应：抑制mRNA的翻译过程，或诱导mRNA降解，实现基因表达的负向调控；核心特点：一个miRNA可靶向数十到上百个基因，实现对整个信号通路的调控，作用位点以细胞质为主，部分可进入细胞核参与表观调控。药物开发的两大方向 1.miRNA抑制剂（Antagomir/AMO）：单链反义核酸，通过完全配对结合内源致病miRNA，阻断其抑制功能，用于治疗miRNA过度表达导致的疾病（如肿瘤、纤维化）； 2.miRNA模拟物（Mimic）：双链RNA，模拟内源抑癌/保护性miRNA的功能，补充其表达不足，用于治疗miRNA下调导致的疾病。核心优势与瓶颈核心优势现存瓶颈可同时调控整个信号通路，适合肿瘤、心血管疾病等多基因复杂疾病多靶点属性导致脱靶风险高，安全性窗口窄分子量小，易修饰，组织穿透性强内源通路存在代偿机制，药效可控性难度大可作为疾病诊断的生物标志物，实现诊疗一体化临床转化难度大，目前暂无获批的miRNA药物临床进展 •核心代表管线：Miravirsen（靶向miR-122，治疗丙肝，已完成II期临床）、MRX34（miR-34a模拟物，治疗实体瘤，I期临床）、RG-101（靶向miR-122，治疗乙肝）； •布局方向：肿瘤、肝纤维化、心血管疾病、神经退行性疾病，是RNA药物领域的前沿探索方向。 3. ASO（反义寡核苷酸，Antisense Oligonucleotide）核心定义与分子本质 ASO是长度为15-30nt的单链合成寡核苷酸（DNA/RNA类似物），通过碱基互补配对靶向RNA，是目前功能最多元、历史最悠久的RNA技术，被称为RNA界的“瑞士军刀”。多元作用机制（核心分4大类） ASO的功能由其靶向位点、化学修饰决定，可实现完全相反的生物学效应： 1.降解型（RNase H依赖）：ASO与靶mRNA形成DNA-RNA杂合双链，招募RNase H酶切割mRNA，实现基因沉默，与siRNA效应一致； 2.剪接调控型：靶向前体mRNA（pre-mRNA）的剪接位点，阻断剪接体的结合，实现外显子跳跃、内含子保留、剪接校正，修复致病的异常剪接（如杜氏肌营养不良DMD、脊髓性肌萎缩症SMA）； 3.翻译抑制型：靶向mRNA的5'UTR或编码区，阻断核糖体与mRNA的结合，抑制蛋白翻译，不降解mRNA； 4.基因激活型（RNAa）：通过表观遗传调控机制靶向基因启动子、增强子区域的非编码RNA，激活内源基因转录，实现基因表达上调（详见RNA激活章节）。关键技术突破 •化学修饰升级：￮第一代：PS硫代修饰，提高核酸酶稳定性，促进蛋白结合；￮第二代：2'-OMe、2'-MOE修饰，降低免疫原性，提高靶标亲和力；￮第三代：锁核酸（LNA）、吗啉代（PMO）、肽核酸（PNA），大幅提高碱基配对亲和力与稳定性，可实现中枢、肌肉等组织的递送，无需复杂的递送系统。核心优势：单链结构无需LNP等纳米载体，可自主穿透细胞膜，组织穿透性远优于双链RNA。核心优势与瓶颈核心优势现存瓶颈功能多元，可实现沉默、剪接、激活等多种效应高剂量下存在脱靶毒性与肝肾毒性风险单链结构易修饰、稳定性强，可直接用于中枢、眼科、肌肉局部给药全身给药的肝外靶向效率仍有提升空间研发周期短，靶点覆盖广，可靶向非编码RNA 部分剪接调控型药物需高频给药，患者依从性有限临床应用与商业化现状 •已获批药物：全球已有超10款ASO药物获批，核心代表为诺西那生钠（SMA治疗，全球首个中枢给药的RNA药物）、Eteplirsen（DMD治疗，外显子跳跃）、Viltolarsen（DMD治疗）、Inotersen（ATTR治疗）； •核心适应症：罕见病（神经肌肉疾病为主）、中枢神经系统疾病、眼科疾病、代谢病、肿瘤。 4. mRNA（信使RNA，Messenger RNA）核心定义与分子本质 mRNA是携带蛋白编码遗传信息的单链RNA，是DNA与蛋白之间的遗传信息传递中间体，药物开发的核心逻辑是将人工设计的mRNA递送至细胞内，让人体细胞自主合成治疗性蛋白，相当于给细胞一个“蛋白生产图纸”。分子结构与核心设计完整的治疗性mRNA包含5个核心元件，每个元件直接决定药效与稳定性： 1.5'帽结构：保护mRNA不被降解，提高翻译效率，降低免疫原性； 2.5'UTR：调控核糖体结合与翻译起始效率； 3.开放阅读框（ORF）：编码目标蛋白的核心序列，可通过密码子优化提高翻译效率； 4.3'UTR：调控mRNA的稳定性与翻译效率； 5.polyA尾：保护mRNA不被降解，延长半衰期。关键技术突破 •化学修饰：假尿嘧啶（Ψ）、N1-甲基假尿嘧啶（m1Ψ）修饰，彻底解决了外源mRNA的固有免疫原性问题，同时大幅提高翻译效率与稳定性，是mRNA技术商业化的核心里程碑； •递送系统：脂质纳米颗粒（LNP）是目前主流的递送载体，可包裹带负电的mRNA，促进细胞内吞与内体逃逸，实现mRNA的细胞质递送，是新冠mRNA疫苗成功的核心支撑。核心应用场景 1.预防性疫苗：新冠疫苗、呼吸道合胞病毒（RSV）疫苗、流感疫苗、带状疱疹疫苗等，是目前最成熟的应用场景； 2.治疗性疫苗：个性化肿瘤新抗原疫苗，是目前最热门的研发方向，BioNTech、Moderna的相关管线已进入III期临床； 3.蛋白替代治疗：补充体内缺失或功能异常的蛋白，如血友病、罕见酶缺乏症； 4.基因编辑与细胞治疗：递送Cas9、碱基编辑器等基因编辑工具，或细胞因子、嵌合抗原受体（CAR），用于体外细胞改造或体内基因编辑； 5.抗体与免疫治疗：在体内表达治疗性抗体、细胞因子，用于肿瘤、自身免疫病治疗。核心优势与瓶颈核心优势现存瓶颈不进入基因组，无插入突变风险，安全性高天然易降解，高度依赖化学修饰与递送系统靶点覆盖无上限，可编码任何治疗性蛋白体内表达时长有限（通常为几天到两周），需重复给药研发与生产速度极快，序列设计仅需几周，无细胞生产体系易于规模化全身给药主要靶向肝脏与脾脏，肝外组织递送效率低可同时编码多个蛋白，实现多价疫苗或联合治疗高剂量下存在免疫原性与炎症反应风险商业化现状 •已获批药物：辉瑞/BioNTech、Moderna的新冠mRNA疫苗，是全球首个获批的mRNA药物； •产业格局：BioNTech、Moderna为全球龙头，国内企业在传染病疫苗、肿瘤疫苗领域已进入临床阶段，技术快速追赶。 5. srRNA（自扩增RNA，Self-Replicating RNA，也叫saRNA）核心定义与分子本质 srRNA是mRNA 2.0技术，在常规mRNA的基础上，整合了RNA病毒的复制元件，进入细胞后可自主完成自我扩增，实现目标蛋白的超高量、长效表达。底层作用机制与结构设计 srRNA的核心结构基于甲病毒（如辛德毕斯病毒、委内瑞拉马脑炎病毒）的基因组设计，包含两大核心模块： 1.复制酶模块：编码RNA依赖的RNA聚合酶（RdRp，复制酶），是srRNA自我扩增的核心； 2.目标蛋白表达模块：通过亚基因组启动子驱动，编码治疗性目标蛋白。作用流程： 1.srRNA进入细胞质后，利用宿主核糖体先翻译出RdRp复制酶； 2.RdRp以srRNA为模板，合成负链RNA中间体； 3.以负链RNA为模板，一方面大量扩增全长srRNA，另一方面大量转录编码目标蛋白的亚基因组mRNA； 4.最终实现目标蛋白的表达量较常规mRNA提升100-1000倍。核心优势与瓶颈核心优势现存瓶颈给药剂量极低（ng级），仅为常规mRNA的1/100-1/1000，大幅降低毒性与生产成本复制酶与扩增过程会激活先天免疫，存在固有免疫原性问题表达时长显著延长，单次给药可维持数周甚至数月，大幅降低给药频率序列长度长（约9-15kb），合成难度与稳定性控制难度高于常规mRNA 疫苗场景下，可同时表达抗原与激活天然免疫，自带佐剂效应，免疫原性远强于常规mRNA 复制的可控性仍需优化，避免过度扩增导致的细胞毒性临床应用与进展 •核心应用场景：下一代传染病疫苗、个性化肿瘤疫苗、蛋白替代治疗、体内基因编辑； •代表企业与管线：Gritstone Bio的新冠、肿瘤疫苗（II期临床）、Arcturus的新冠疫苗（已获批紧急使用）、辉瑞/Moderna均布局了srRNA下一代疫苗平台，国内企业已进入临床前研究阶段。注：需注意命名区分，srRNA（自扩增RNA）也常被缩写为saRNA，与小激活RNA（small activating RNA，也叫saRNA）缩写一致，行业内通常用srRNA指代自扩增RNA，避免混淆。 6. AOC（抗体-寡核苷酸偶联物，Antibody-Oligonucleotide Conjugate）核心定义与分子本质 AOC是继ADC（抗体-药物偶联物）之后的新一代抗体偶联技术，由靶向抗体、可裂解连接子、核酸载荷三部分组成，核心价值是彻底解决RNA药物的肝外递送痛点，实现全组织、全细胞的精准靶向。结构设计与作用机制 1.三大核心元件：￮抗体模块：通常为单克隆抗体、Fab片段或scFv，靶向靶细胞表面特异性表达的膜抗原（需具备受体介导的内吞能力），相当于“精准导航系统”；￮连接子（Linker）：连接抗体与核酸载荷，分为可裂解型（酸性环境、溶酶体酶敏感型）与不可裂解型，决定了载荷的释放效率；￮核酸载荷：通常为siRNA、ASO、saRNA，是发挥药效的核心“弹头”，药物抗体比（DAR值）是核心设计参数，通常为2-4。 2.作用流程：￮抗体特异性识别靶细胞表面抗原，通过受体介导的内吞进入细胞；￮内吞形成的内涵体酸化，连接子裂解，核酸载荷释放；￮核酸载荷逃逸至细胞质/细胞核，发挥基因沉默、剪接调控或激活的药效。核心颠覆性价值目前已商业化的RNA药物（siRNA/ASO），90%以上仅能靶向肝脏（GalNAc修饰），而AOC彻底打破了这一限制： •可靶向肝脏以外的任何组织，包括肌肉、心脏、中枢神经系统、肾脏、肿瘤等； •保留了抗体的高特异性与核酸药物的高药效，同时大幅降低全身给药的脱靶毒性； •可拓展RNA药物的适应症边界，从肝脏疾病、罕见病拓展至更广泛的慢性病、肿瘤、神经疾病。核心优势与瓶颈核心优势现存瓶颈实现RNA药物的肝外精准靶向，拓展了RNA药物的应用天花板核酸载荷分子量大、带负电，内体逃逸效率低，是目前最大的技术卡点结合了抗体的高特异性与核酸药物的靶点覆盖优势，可靶向“不可成药”靶点分子量较大，组织穿透性有限，实体瘤与中枢递送仍需优化可实现长效给药，降低给药频率，提升患者依从性偶联工艺复杂，DAR值均一性控制难度大，规模化生产成本高免疫原性低于ADC，安全性窗口更宽存在抗体相关的免疫原性与清除问题临床进展与产业格局 •全球龙头：Avidity Biosciences，其核心管线AOC1001（靶向转铁蛋白受体TfR1，载荷为抗DMD的siRNA）治疗杜氏肌营养不良，已公布的I/II期临床数据显示可显著提升肌营养不良蛋白表达，是全球首个进入临床的AOC药物； •产业合作：诺华与Avidity达成超120亿美元的全球合作，罗氏、礼来、强生等MNC均通过合作或自研布局AOC平台； •国内进展：多家Biotech企业已布局AOC平台，针对DMD、罕见病、肿瘤的管线进入临床前研究阶段。 7. RNA激活（RNAa，RNA Activation）核心定义与分子本质 RNA激活是与RNA干扰（RNAi）完全相反的技术，指通过小激活RNA（saRNA，21-23nt双链RNA）或激活型ASO，靶向基因的启动子、增强子等调控区域，上调内源有益基因的转录与表达，是RNA药物领域最具颠覆性的前沿方向。底层作用机制 RNA激活的作用位点为细胞核，与siRNA的细胞质作用完全不同，目前主流的机制假说为表观遗传调控，分为两类： 1.组蛋白修饰机制（主流）： saRNA/激活型ASO靶向基因启动子区域，招募组蛋白修饰复合物（如组蛋白乙酰化酶、甲基转移酶），使启动子区域的染色质从紧密的异染色质转化为疏松的常染色质，促进转录因子与启动子的结合，从而启动靶基因的转录，实现内源基因表达上调。 2.非编码RNA抑制机制：靶向基因启动子区域转录的负向调控非编码RNA（如lncRNA、eRNA），抑制其对靶基因的转录阻遏作用，从而解除基因沉默，激活转录。核心特点：激活的是细胞自身的内源基因，可表达所有天然的蛋白亚型，符合生理调控规律，且表观遗传修饰的改变可实现长效激活，单次给药药效可维持数月。核心优势与瓶颈核心优势现存瓶颈解决了“基因表达不足”的疾病需求，填补了siRNA/ASO仅能沉默的空白作用机制尚未完全阐明，靶点筛选与有效序列设计难度大激活内源基因，可表达所有天然蛋白亚型，比mRNA更符合生理状态，无过度表达风险作用位点为细胞核，对递送系统的入核效率要求更高长效性突出，表观遗传调控的效应可维持数月，给药频率远低于mRNA 临床转化处于早期，暂无获批药物，成药性仍需验证可靶向传统技术无法解决的疾病，如神经退行性疾病、衰老相关疾病、糖尿病存在非特异性表观调控的脱靶风险，安全性需长期验证临床应用与进展 •核心适应症：肿瘤（激活抑癌基因，如PTEN、p53、p21）、神经退行性疾病（激活神经营养因子，如BDNF）、糖尿病（激活胰岛素或胰岛素敏感性相关基因）、罕见病、衰老相关疾病； •代表企业与管线：MiNA Therapeutics的MTL-CEBPA（激活CEBPA基因，治疗肝癌，已完成II期临床）、Alnylam、Ionis均布局了激活型ASO管线，国内多家企业已进入临床前研究阶段。三、7大技术横向深度对比总表技术分子本质核心作用作用位点作用方向核心递送系统商业化阶段核心不可替代价值 siRNA 21-23nt双链RNA 切割靶mRNA，沉默基因细胞质基因下调 GalNAc、LNP、AOC 已商业化（多款药物获批）肝脏靶向疾病的长效沉默，成熟度最高 miRNA 20-24nt单链RNA（内源）多靶点调控基因表达细胞质为主可上调/下调化学修饰、GalNAc 临床阶段（暂无获批药物）多基因复杂疾病的通路调控 ASO 15-30nt单链寡核苷酸沉默、剪接调控、基因激活细胞质+细胞核可上调/下调化学修饰、局部给药已商业化（多款药物获批）功能最多元，无需载体，可实现中枢/眼科局部给药 mRNA 单链编码RNA 指导细胞合成治疗性蛋白细胞质蛋白表达（上调） LNP、脂质纳米载体已商业化（新冠疫苗）可编码任何蛋白，无基因组整合风险 srRNA 带复制元件的mRNA 自我扩增，超高量表达目标蛋白细胞质蛋白表达（上调） LNP、VLP 临床阶段极低剂量、长效表达，下一代mRNA疫苗核心技术 AOC 抗体-核酸偶联物抗体介导的核酸精准递送全组织随核酸载荷而定抗体靶向递送临床阶段实现RNA药物的肝外全组织靶向，拓展RNA药物天花板 RNA激活 saRNA/激活型ASO 激活内源有益基因转录细胞核基因上调 LNP、GalNAc、AOC 临床阶段解决基因表达不足的疾病，长效内源调控四、产业发展趋势与未来展望 1.递送技术是核心竞争壁垒：从肝脏靶向到全组织靶向，AOC、新型LNP、外泌体、病毒样颗粒（VLP）等递送技术将成为RNA药物的核心竞争力，肝外递送的突破将带来RNA药物适应症的爆发式增长。 2.功能从“单向沉默”到“双向调控”：RNA激活技术的成熟，将实现RNA药物从“关基因”到“开+关基因”的双向调控，覆盖几乎所有疾病类型，彻底打开RNA药物的市场空间。 3.技术融合成为主流方向：AOC与srRNA、RNA激活的结合，mRNA与基因编辑的结合，siRNA与ASO的联合用药，将实现不同技术的优势互补，解决单一技术的瓶颈。 4.适应症从罕见病向慢性病拓展：随着长效性、递送技术的突破，RNA药物将从罕见病，逐步拓展至高血脂、高血压、糖尿病、神经退行性疾病等慢性病领域，成为继小分子、抗体之后的第三大类药物。 5.国产化替代加速：国内企业在siRNA、ASO、mRNA、AOC等领域的技术快速追赶，化学修饰、递送系统的核心专利逐步突破，未来3-5年将迎来国产RNA药物的商业化爆发期。 siRNA / ASO / mRNA / srRNA / AOC / RNA激活深度全景解析精简版全是研发+投资+产业判断的干货，不绕弯。一、6大RNA技术一句话定位（最关键） 1.siRNA：沉默基因→ 关掉坏蛋白 2.ASO：多功能核酸→ 沉默、剪接、激活都能干 3.mRNA：给细胞图纸→ 造好蛋白 4.srRNA（saRNA）：自带复制机的mRNA → 超强、超省量 5.AOC：抗体+siRNA/ASO → 精准打到肝外任何组织 6.RNA激活（saRNA/RNAa）：激活好基因→ 打开有用的蛋白二、逐点深度拆解（原理+为什么强+应用+代表） 1）siRNA —— 基因沉默“标准武器” 原理双链RNA，进入细胞后组装成RISC复合体，特异性切割靶mRNA，让坏基因不表达。优势 •特异性极强 •沉默效率极高 •搭配GalNAc可实现半年一针短板 •只能沉默，不能激活 •肝外递送难应用高血脂、肝病、罕见病、代谢病代表 Inclisiran（诺华）、Givosiran（Alnylam） 2）ASO —— RNA界的“瑞士军刀” 原理单链DNA/RNA类似物，通过碱基配对调控RNA。能干 4 件事 1.沉默基因（降解mRNA） 2.exon skipping 外显子跳跃（SMA、杜氏肌营养不良） 3.剪接调控 4.激活基因（RNAa）优势 •分子量小、组织穿透强 •可做脑、眼、肌肉 •历史最长、最成熟短板 •需大量化学修饰 •高剂量可能有毒性代表诺西那生钠（SMA）、Ionis 全平台 3）mRNA —— 让细胞变成“药物工厂” 原理给细胞一段编码蛋白的RNA → 细胞自己造蛋白。定位 •疫苗 •蛋白替代 •细胞因子/抗体表达 •基因编辑（表达Cas9）优势 •不进基因组、安全 •研发极快 •可编码任何蛋白短板 •不稳定、需要递送 •表达时间短（几天～两周）代表新冠疫苗、BioNTech/Moderna 全管线 4）srRNA = saRNA 自扩增RNA —— mRNA 2.0 核弹级原理 mRNA + 病毒复制酶基因进入细胞→ 自己复制自己 → 表达量暴增100～1000倍优势 •剂量极低（ng级） •表达时间超长（数月） •免疫原性更强（疫苗神器）定位下一代疫苗、慢性病、蛋白替代一句话 srRNA = 自带放大器的mRNA 5）AOC 抗体核酸偶联 —— 肝外递送王者结构 Antibody + siRNA/ASO 抗体 = 导航核酸 = 药效原理抗体精准识别细胞表面抗原→ 把RNA带进细胞。颠覆性 •真正肝外递送：肌肉、神经、心脏、肿瘤 •效率高、毒性低 •下一代RNA药物核心平台代表 Avidity（临床阶段）诺华 120亿美元合作一句话 AOC = RNA药物的“精准制导系统” 6）RNA激活（RNAa / saRNA）—— 最被低估的颠覆性方向原理和siRNA相反： siRNA：关基因 RNA激活：开基因通过靶向基因启动子/非编码区，上调好基因表达。能治什么？ •基因表达不足的病 •神经退行性疾病 •衰老相关疾病 •糖尿病、代谢病优势 •全新机制，无竞争对手 •很多病是“缺蛋白”，不是“坏蛋白太多” 代表 MiRagen、中外多家新锐一句话 siRNA是删bug，RNA激活是开外挂。三、6大技术终极对比（最精华）技术作用方向递送爆发点 siRNA 沉默基因关坏基因肝（GalNAc）慢性病 ASO 沉默/剪接/激活多功能脑/眼/肝罕见病 mRNA 造蛋白疫苗/蛋白替代 LNP 疫苗 srRNA 自复制造蛋白超强表达 LNP/VLP mRNA下一代 AOC 抗体+RNA 精准肝外全组织肝外递送 RNA激活激活好基因上调功能全组织衰老/神经四、行业内部终极判断（你记住这个就够） •现在最赚钱：siRNA •最成熟广谱：ASO •现在最大市场：mRNA •下一代mRNA：srRNA •肝外递送王者：AOC •最被低估、未来最大空间：RNA激活科学智能：在先进产业场景中构建“状态感知-实时认知-自主决策-精准执行-学习提升”的科学智能（Science_and_AI）；实现产业转型升级、DT驱动业务、价值创新创造的产业互联生态链。先进产业+物理AI=科学智能产业智能官：Science_and_AI 加入知识星球“产业智能研究院”：产业OT技术（自动化+机器人+工艺+精益）和新一代IT技术（云计算+物联网+区块链+大数据+人工智能）深度融合，在场景中构建“状态感知-实时认知-自主决策-精准执行-学习提升”的科学智能（Science_and_AI）；实现产业转型升级、DT驱动业务、价值创新创造的产业互联生态链。科学智能（Science_and_AI）作为第四次工业革命的核心驱动力，将进一步释放历次科技革命和产业变革积蓄的巨大能量，并创造新的强大引擎；重构设计、生产、供应链和服务等经济活动各环节，形成从宏观到微观各领域的智能化新需求，催生新技术、新产品、新产业、新业态和新模式；引发经济结构重大变革，深刻改变人类生产生活方式和思维模式，实现社会生产力的整体跃升。产业智能化技术分支用来的今天，从业者必须了解如何将科学智能（Science_and_AI）全面渗入整个公司、产品、业务等商业场景中，利用科学智能（Science_and_AI）形成数字化、网络化和智能化力量，实现行业的重新布局、企业的重新构建和焕然新生。版权声明：产业智能官（ID：Science_and_AI）发表的文章，除非确实无法确认，我们都会注明作者和来源，涉权请联系协商解决，联系、投稿邮箱：wolongzy@qq.com

siRNA信使RNA核酸药物寡核苷酸临床研究

2026-02-19

·PRNewswire

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance – – Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively – – Cash of $1.95B as of December 31, 2025 – WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025. "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs, and strong financial position, we look forward to continued success as we approach cash flow breakeven." Key Corporate Highlights Full-year 2025 product and royalty revenue of $831 million, exceeding guidance Global launch of Sephience off to strong start Q4 2025 revenue of $92 million, including $81 million revenue in the US and $11 million revenue ex-US Sephience total net revenue of $111 million in 2025 since launch 946 total patients on commercial therapy worldwide as of December 31, 2025 1,134 patient start forms received in the US as of December 31, 2025 Approval in Japan in December 2025; approval in Brazil in February 2026 Sephience global footprint expected to increase to 20 to 30 countries by end of 2026 In December 2025, PTC sold the remainder of its Evrysdi® (risdiplam) royalty to Royalty Pharma for $240 million upfront and up to $60 million in sales-based milestones; PTC maintains the right to receive a $150 million milestone from Roche based on single-year Evrysdi sales of $2.5 billion End-of-Phase 2 meeting with FDA held in Q4 2025 to discuss the votoplam Huntington's disease (HD) program Alignment reached on design of global Phase 3 trial, INVEST-HD, which is planned to initiate in 1H 2026 FDA confirmed openness for potential Accelerated Approval pathway given significant unmet need Type C meeting with FDA held in December 2025 to discuss the vatiquinone Friedreich's ataxia program; FDA indicated that an additional study would be necessary to support NDA resubmission and meeting minutes stated that this could be an open-label study with a natural history control group Fourth Quarter and Full Year 2025 Financial Highlights Total revenues were $164.7 million for the fourth quarter of 2025, compared to $213.2 million for the fourth quarter of 2024. Total revenues were $1,730.7 million for full year 2025, compared to $806.8 million for full year 2024. Included in total revenues is collaboration and license revenue of $998.4 million for the full year 2025, related to the votoplam license and collaboration agreement with Novartis, which closed in January 2025. Total net product revenues were $184.0 million for the fourth quarter of 2025, compared to $150.1 million for the fourth quarter of 2024. Total net product revenues were $586.7 million for full year 2025, compared to $582.1 million for full year 2024. Translarna™ (ataluren) net product revenues were $39.0 million for the fourth quarter of 2025, compared to $89.1 million for the fourth quarter of 2024. Translarna net product revenues were $235.3 million for full year 2025, compared to $321.1 million for full year 2024. Emflaza® (deflazacort) net product revenues were $27.1 million for the fourth quarter of 2025, compared to $50.5 million for the fourth quarter of 2024. Emflaza net product revenues were $146.4 million for full year 2025, compared to $207.2 million for full year 2024. Roche reported Evrysdi full year 2025 sales of approximately 1,757 CHF million, resulting in royalty revenue of $244.2 million to PTC for full year 2025, compared to $203.9 million to PTC for full year 2024. Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&D expenses were $133.1 million for the fourth quarter of 2025, compared to $124.8 million for the fourth quarter of 2024. GAAP R&D expenses were $455.2 million for full year 2025, compared to $534.5 million for full year 2024. Non-GAAP R&D expenses were $124.3 million for the fourth quarter of 2025, excluding $8.8 million in non-cash, stock-based compensation expense, compared to $116.0 million for the fourth quarter of 2024, excluding $8.8 million in non-cash, stock-based compensation expense. Non-GAAP R&D expenses were $419.6 million for full year 2025, excluding $35.7 million in non-cash, stock-based compensation expense, compared to $497.9 million for full year 2024, excluding $36.6 million in non-cash, stock-based compensation expense. GAAP SG&A expenses were $96.9 million for the fourth quarter of 2025, compared to $84.7 million for the fourth quarter of 2024. GAAP SG&A expenses were $347.1 million for full year 2025, compared to $300.9 million for full year 2024. Non-GAAP SG&A expenses were $87.2 million for the fourth quarter of 2025, excluding $9.7 million in non-cash, stock-based compensation expense, compared to $76.3 million for the fourth quarter of 2024, excluding $8.4 million in non-cash, stock-based compensation expense. Non-GAAP SG&A expenses were $308.3 million for full year 2025, excluding $38.9 million in non-cash, stock-based compensation expense, compared to $262.9 million for full year 2024, excluding $38.0 million in non-cash, stock-based compensation expense. Net loss was $135.0 million for the fourth quarter of 2025, compared to net loss of $65.9 million for the fourth quarter of 2024. Net income was $682.6 million for full year 2025, compared to net loss of $363.3 million for full year 2024. Cash, cash equivalents, and marketable securities were $1,945.4 million on December 31, 2025, compared to $1,139.7 million on December 31, 2024. Shares issued and outstanding as of December 31, 2025, were 81,474,366. Full Year 2026 Financial Guidance Total product revenue of $700 to $800 million, representing a 19 to 36% increase from 2025, with the majority from Sephience GAAP R&D and SG&A expense of $775 to $815 million Non-GAAP R&D and SG&A expense of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million Non-GAAP Financial Measures In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below. Acronyms CHF: Confoederatio Helvetica Francs (Swiss francs) DMD: Duchenne muscular dystrophy FA: Friedreich's ataxia FDA: U.S. Food and Drug Administration GAAP: Generally Accepted Accounting Principles HD: Huntington's disease NDA: New Drug Application nmDMD: Nonsense mutation Duchenne muscular dystrophy PKU: Phenylketonuria R&D: Research and Development SG&A: Selling, General, and Administrative Today's Conference Call and Webcast Reminder To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at . A replay of the call will be available after completion of the call and will be archived on the company's website. About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit and follow on LinkedIn, X, Instagram and Facebook. For more Information Investors Ellen Cavaleri +1 (615) 618-6228 [email protected] Media Jeanine Clemente +1 (908) 912-9406 [email protected] Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "Full Year 2026 Financial Guidance", including with respect to (i) 2026 total product revenue guidance and (ii) 2026 GAAP and non-GAAP R&D and SG&A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, meetings with regulatory agencies, commercialization and other matters with respect to its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance," "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," "aim," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including any regulatory submissions and potential approvals, commercialization, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in geographies in which it has been approved and the effect of the European Commission's adoption of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on Translarna and the withdrawal of the Translarna NDA in the U.S. on other regulatory bodies; expectations with respect to PTC's license and collaboration agreement with Novartis Pharmaceuticals Corporation for votoplam for the treatment of Huntington's disease including its right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis, the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses, including potential accelerated approval; expectations with respect to Upstaza/Kebilidi, including commercialization, manufacturing capabilities, and the potential achievement of sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to vatiquinone, including with respect to the design and expected timing of clinical trials and studies, the availability of data, and regulatory submissions and responses and potential approvals and other matters; expectations with respect to the commercialization of Evrysdi under PTC's SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of its lease agreements; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience, Translarna, Emflaza, Upstaza, Kebilidi, Evrysdi, Tegsedi or Waylivra. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law. SOURCE PTC Therapeutics, Inc. 21% more press release views with Request a Demo

财报临床3期引进/卖出上市批准申请上市

100 项与伊诺特森相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10941	-	N07XX15	DB14713

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
淀粉样神经病	加拿大	Akcea Therapeutics, Inc.	2019-01-07
家族性淀粉样神经病	加拿大	Ionis Pharmaceuticals, Inc.	2018-10-03
遗传性转甲状腺素蛋白淀粉样变性	欧盟	Akcea Therapeutics Ireland Ltd.	2018-07-06
遗传性转甲状腺素蛋白淀粉样变性	冰岛	Akcea Therapeutics Ireland Ltd.	2018-07-06
遗传性转甲状腺素蛋白淀粉样变性	列支敦士登	Akcea Therapeutics Ireland Ltd.	2018-07-06
遗传性转甲状腺素蛋白淀粉样变性	挪威	Akcea Therapeutics Ireland Ltd.	2018-07-06
多发性神经病	欧盟	Akcea Therapeutics Ireland Ltd.	2018-07-06
多发性神经病	冰岛	Akcea Therapeutics Ireland Ltd.	2018-07-06
多发性神经病	列支敦士登	Akcea Therapeutics Ireland Ltd.	2018-07-06
多发性神经病	挪威	Akcea Therapeutics Ireland Ltd.	2018-07-06

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
老年性心脏淀粉样变性	临床2期	-	Ionis Pharmaceuticals, Inc.	2016-01-01
老年性心脏淀粉样变性	临床2期	-	GSK Plc	2016-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04306510 (CTgov)	临床4期	遗传性转甲状腺素蛋白淀粉样变性	8	TEGSEDI	鑰蓋簾鹽網繭製簾構憲 = 夢鹽淵簾簾憲淵鬱遞糧積選憲構壓簾衊廠襯淵 (顧窪鬱鏇構鏇願築膚衊, 衊襯餘築衊窪蓋蓋廠願 ~ 簾選觸範壓積鏇網築醖) 更多	-	2025-04-10
NCT02175004 (NEURO-TTR \| OLE, CTgov)	临床3期	家族性淀粉样神经病	135	Inotersen (Previous Placebo-Inotersen 300 mg)	齋鏇襯鬱壓衊構網願製 = 鏇壓積壓廠憲壓膚獵蓋壓觸遞膚選選衊遞構襯 (鬱選齋選願遞製醖憲醖, 獵襯醖鏇衊獵糧鏇鹹糧 ~ 艱選淵鹹夢艱製壓衊築) 更多	-	2023-02-09
				Inotersen (Previous Inotersen-Inotersen 300 mg)	齋鏇襯鬱壓衊構網願製 = 壓廠願簾艱艱壓淵廠衊壓觸遞膚選選衊遞構襯 (鬱選齋選願遞製醖憲醖, 願遞簾遞遞艱齋鑰觸壓 ~ 鏇糧膚積製選選膚襯獵) 更多
NCT02175004 (OLE, Pubmed \| J Neurol) 人工标引	临床3期	遗传性转甲状腺素蛋白淀粉样变性	109	inotersen (inotersen-inotersen)	餘窪夢鬱選艱鬱襯鬱膚(選餘獵窪鏇鑰糧積餘鏇) = 襯簾顧遞淵鑰範願淵醖鹹願顧繭夢齋鏇鏇壓衊 (膚築膚鏇願襯餘築窪鏇 )	积极	2022-07-31
				inotersen (placebo-inotersen)	餘窪夢鬱選艱鬱襯鬱膚(選餘獵窪鏇鑰糧積餘鏇) = 憲繭膚網醖艱餘製窪鏇鹹願顧繭夢齋鏇鏇壓衊 (膚築膚鏇願襯餘築窪鏇 )
NCT01737398 (Pubmed \| Nucleic Acid Ther)	临床2/3期	家族性淀粉样神经病	173	Inotersen	構夢淵艱鹹鹹憲鏇鹹製(廠鬱窪蓋遞鹽夢鹹蓋構) = 夢憲糧鹹簾鬱遞積積鹹鹽淵憲襯製鑰鹽顧構餘 (鏇醖餘憲願糧蓋醖積壓 )	-	2020-10-01
NCT02175004 (NEURO-TTR, Pubmed \| Eur J Neurol) 人工标引	临床3期	遗传性转甲状腺素蛋白淀粉样变性	135	inotersen (received inotersen in NEURO-TTR)	醖構餘遞網積廠齋夢鑰(壓襯襯鹽蓋餘壓網顧構) = 鹽鑰鹹選蓋壓網範鏇鏇襯淵膚艱構壓夢鹽選齋 (選鏇艱蓋鏇蓋鏇夢鬱觸 ) 更多	积极	2020-08-01
				inotersen (received placebo in NEURO-TTR)	醖構餘遞網積廠齋夢鑰(壓襯襯鹽蓋餘壓網顧構) = 簾積壓鏇襯醖鹽醖餘膚襯淵膚艱構壓夢鹽選齋 (選鏇艱蓋鏇蓋鏇夢鬱觸 ) 更多
NCT02175004 \| NCT01737398 (NEURO-TTR, AAN2020)	临床3期	家族性淀粉样神经病	135	Inotersen	範築鹽簾憲餘遞網選製(衊艱製鹹顧廠鹽鹽鏇齋) = 鹹鏇襯衊願鹽餘網膚構襯壓製鏇襯鏇淵糧製壓 (網築憲窪鹹蓋鬱憲鑰廠 ) 更多	积极	2020-04-14
				Placebo	範築鹽簾憲餘遞網選製(衊艱製鹹顧廠鹽鹽鏇齋) = 醖構觸鏇鬱艱壓糧遞蓋襯壓製鏇襯鏇淵糧製壓 (網築憲窪鹹蓋鬱憲鑰廠 ) 更多
NCT01737398 (NEURO-TTR, CTgov)	临床2/3期	家族性淀粉样神经病	173	Inotersen (Inotersen)	範膚鹽餘衊鹽簾壓顧範(齋憲鬱淵淵獵襯網願鏇) = 願鬱願窪齋窪艱襯獵網製觸窪廠窪窪鏇膚膚觸 (積製範繭網鬱醖繭遞夢, 15.672) 更多	-	2019-01-23
				Placebo (Placebo)	範膚鹽餘衊鹽簾壓顧範(齋憲鬱淵淵獵襯網願鏇) = 觸範衊鑰簾餘艱夢艱廠製觸窪廠窪窪鏇膚膚觸 (積製範繭網鬱醖繭遞夢, 24.190) 更多
NCT01737398 (Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床3期	遗传性转甲状腺素蛋白淀粉样变性	172	Inotersen	蓋積蓋襯鏇鏇夢鏇窪餘(獵憲糧廠鏇製網夢窪夢): difference = -11.7 (95% CI, -18.3 ~ -5.1), P-Value = <0.001 更多	积极	2018-07-05
				Placebo